Greenwich LifeSciences, Inc.
Financial highlights
| Metric | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 | FY 12/31/20 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $13.0M | $7.7M | $6.5M | $3.6M | $1.1M |
| Operating expenses | $16.0M | $9.3M | $8.0M | $4.6M | $1.9M |
| Operating income | -$16.0M | -$9.3M | -$8.0M | -$4.6M | -$1.9M |
| Net income | -$15.8M | -$8.9M | -$7.8M | -$4.6M | -$1.9M |
| Balance Sheet | |||||
| Cash and equivalents | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M |
| Current assets | — | — | — | — | $28.7M |
| Total assets | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M |
| Current liabilities | $1.6M | $294,406 | $262,905 | $385,172 | $1.0M |
| Total liabilities | $1.6M | $294,406 | $262,905 | $385,172 | $1.0M |
| Stockholders' equity | $2.5M | $6.7M | $13.2M | $26.8M | $27.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.3M | -$6.5M | -$6.2M | -$4.3M | -$1.2M |
| Stock-based compensation | $7.3M | $2.4M | $1.7M | $660,582 | $677,988 |
| Share repurchases | — | $7.5M | $7.5M | — | — |
Shares outstanding 14.7M
Annual filing data through FY ended December 31, 2024; float as of July 15, 2026.